ClinicalTrials.gg
CompletedNCT00425204Updated Sep 15, 2008

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

A Phase 2 interventional study of Panitumumab (ABX-EGF) in Colorectal Cancer, Non-Small Cell Lung Cancer and Prostate Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
63rd of 88
31 · median 70
Started
2004
with 3 others
Phase 2
60 of 90
3 open now
Registered
16th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 63rd largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 60 in phase 2, and was the 16th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment

03

Conditions studied

  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Prostate Cancer
  • Solid Tumors
  • Advanced Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and sign an IRB approved Form
  • Male or female 18 years of age or older
  • Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted , double barrier birth control, or an intrauterine device (IUD) and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment and during the course of the study
  • Previously received and tolerated panitumumab treatment on studies 20020374 Part 2 or 20030138/20040116
  • Is considered "stable" or "responding" based on the (20020374 Part 2) or WHO (20040116) criteria, at the final treatment visit of the previous panitumumab clinical trial and the screening visit for this study
  • No more than 2 months (60 days) have elapsed since the final treatment visit of the previous panitumumab clinical trial
  • score > or = 70%

Exclusion criteria

Exclusion Criteria:

  • (20040116 patients are allowed only if controlled and asymptomatic)
  • Uncontrolled hypercalcemia (calcium level outside the ; antihypercalcemic treatment is allowed). Exception: Patients in the Motzer Intermediate Risk Group from 20020374 Cohort 2 with uncontrolled high corrected calcium (>10 mg/dl) may be enrolled
  • Use of any anti-tumor therapy or drug, other than panitumumab, between the last visit of the previous panitumumab study and the initial visit in this 20020375 study
  • Prior treatment with another anti-EGFr agent, other than panitumumab
  • Myocardial infarction within 1 year prior to entering the study
  • Has other cancer that has been active and required treatment within the past 5 years (basal cell carcinoma or cervical carcinoma in situ are allowed)
  • Pregnant or breast feeding female; female of (defined as: post menarche and is biologically capable of becoming pregnant) unwilling to use (as defined in the inclusion criteria) during and for 6 months following treatment
  • Male patient unwilling to use birth control (as defined in the inclusion criteria) during and for 1 month following treatment
  • Known to be positive
  • History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study drug administration
  • Allergy to the ingredients of the study medication or to Staphylococcus Protein A
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Open Label

    Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.

    Drug: Panitumumab (ABX-EGF)

Interventions

  • Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.

06

What researchers measure

Primary outcomes

  1. To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116

    Time frame: Until disease progression, an AE or withdrawn consent

Secondary outcomes

  1. To assess the safety of multidose administration of panitumumab in subjects who received continued and extended panitumumab treatment

    Time frame: Until disease progression, an AE or withdrawn consent

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Sep 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2007
First posted
Jan 22, 2007
Start
Mar 2004
Primary completionActual
Sep 2007
CompletionActual
Mar 2008
Last update
Sep 15, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00425204
Lead sponsor
Amgen
First posted
Jan 22, 2007
Start date
Mar 2004
Primary completion
Sep 2007
Completion
Mar 2008
Last update
Sep 15, 2008

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion